Valuation: Caplin Point Laboratories Limited

Market Cap 216B 2.25B 1.97B 1.86B 1.7B 3.18B 3.2B 22.3B 8.64B 110B 8.44B 8.26B 354B P/E 2027 *
29.7x
P/E 2028 * 25.6x
Enterprise Value 216B 2.25B 1.97B 1.86B 1.7B 3.18B 3.2B 22.3B 8.64B 110B 8.44B 8.26B 354B EV / Sales 2027 *
8.6x
EV / Sales 2028 * 7.61x
Free-Float
26.56%
Yield 2027 *
0.14%
Yield 2028 * 0.14%
1 day-1.05%
1 week+3.20%
Current month+12.65%
1 month+12.58%
3 months+13.10%
6 months+77.72%
Current year+54.02%
1 week 2,710
Extreme 2710
2,990.6
1 month 2,490.35
Extreme 2490.35
2,990.6
Current year 1,502.45
Extreme 1502.45
2,990.6
1 year 1,502.45
Extreme 1502.45
2,990.6
3 years 950
Extreme 950
2,990.6
5 years 575
Extreme 575
2,990.6
10 years 180
Extreme 180
2,990.6
Manager TitleAgeSince
Chief Executive Officer 71 2015-03-27
Director of Finance/CFO - 2016-02-18
Chief Administrative Officer - -
Director TitleAgeSince
Director/Board Member - 2026-01-30
Chairman 73 2010-01-26
Director/Board Member - 2025-11-04
Change 5-day change 1-year change 3-year change Capi.($)
-1.05%+3.20%+39.19%+179.51% 2.25B
+0.12%+0.81%+16.73%+64.52% 46.37B
+1.09%+0.36%+43.72%+108.13% 37.26B
+2.00%+3.78%+23.48%+101.30% 12.53B
+0.05%+0.37%-6.65%+20.29% 11.8B
0.00%0.00%+17.65%+141.86% 8.97B
+1.43%+2.22%+41.73%-13.30% 7.29B
-1.34%-2.73%+27.74%+37.90% 7.09B
-2.07%-2.75%+20.71%+212.23% 7.01B
-2.45%-0.59%-50.18%+3.88% 4.99B
Average -0.22%+0.47%+17.41%+85.63% 14.56B
Weighted average by Cap. +0.30%+0.58%+22.42%+81.64%

Financials

2027 *2028 *
Net sales 25.07B 262M 230M 217M 198M 370M 372M 2.59B 1B 12.81B 982M 961M 41.17B 28.34B 296M 259M 245M 223M 418M 421M 2.93B 1.14B 14.48B 1.11B 1.09B 46.53B
Net income 7.26B 75.79M 66.51M 62.82M 57.24M 107M 108M 752M 291M 3.71B 285M 278M 11.93B 8.41B 87.76M 77.01M 72.73M 66.28M 124M 125M 870M 337M 4.3B 329M 322M 13.81B
Net Debt - -
Logo Caplin Point Laboratories Limited
Caplin Point Laboratories Limited is an India-based pharmaceutical company with a business model catering predominantly to emerging markets of Latin America and Africa. The Company has also entered regulated markets such as the United States through its Subsidiary, Caplin Steriles Limited. The Company's operations include research & development and manufacturing of finished formulations, active pharmaceutical ingredients (APIs), clinical research, front-end generic presence in Latin America, brand marketing in Francophone Africa and a USFDA/EU-GMP approved injectable facility. In the Regulated Markets, its products include liquid & lyophilized vials, pre-filled syringes, three-pc ophthalmic droppers and pre-mix bags. In the Emerging Markets, its products include tablets, dry syrups - bottles, soft gels, capsules, suppositories, liquid syrups - bottles, liquid injectables in ampoules & vials, lyophilized vials, prefilled syringes (PFS), and emulsion injection in ampoules & vials.
Employees
4,199
Date Price Change Volume
26-09-25 ₹2,835.80 -1.05% 7,981
26-09-24 ₹2,865.80 +2.67% 58,430
26-09-23 ₹2,791.30 +0.43% 7,046
26-09-22 ₹2,779.30 +0.81% 11,181
26-09-21 ₹2,756.90 +0.33% 3,266
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2,835.80INR
Average target price
2,765.00INR
Spread / Average Target
-2.50%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CAPLIPOINT Stock